Nonpathogenic Escherichia coli Strain Nissle1917 Prevents Murine Acute and Chronic Colitis

@article{Kamada2005NonpathogenicEC,
  title={Nonpathogenic Escherichia coli Strain Nissle1917 Prevents Murine Acute and Chronic Colitis},
  author={Nobuhiko Kamada and Nagamu Inoue and Tadakazu Hisamatsu and Susumu Okamoto and Katsuyoshi Matsuoka and Toshiro Sato and Hiroshi Chinen and Kyong Su Hong and Takaya Yamada and Yumiko Suzuki and Tatsuo Suzuki and Noriaki Watanabe and Kanji Tsuchimoto and Toshifumi Hibi},
  journal={Inflammatory Bowel Diseases},
  year={2005},
  volume={11},
  pages={455–463}
}
Background: Nonpathogenic Escherichia coli strain Nissle1917 has been used as a probiotics in human inflammatory bowel disease; however, there are few reports examining its therapeutic effect on animal colitis models, and its therapeutic mechanisms remain unknown. The aim of this study was to elucidate the therapeutic effect and mechanism of Nissle1917 using murine acute and chronic colitis models. Methods: Two models were used. (1) Acute model: colitis was induced by administration of 1.3… 

Nonpathogenic Escherichia coli Strain Nissle 1917 Inhibits Signal Transduction in Intestinal Epithelial Cells

The nonpathogenic E. coli strain Nissle 1917 expresses a direct anti-inflammatory activity on human epithelial cells via a secreted factor which suppresses TNF-α-induced IL-8 transactivation through mechanisms different from NF-κB inhibition.

Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity

Evaluation of colitis severity induced in rodent fed with E. coli Nissle 1917 or an isogenic non-genotoxic mutant demonstrated the need for a functional biosynthetic pathway both in the amelioration of the disease and in the modulation of cytokine expression.

Probiotic Escherichia coli Nissle 1917 and Commensal E. coli K12 Differentially Affect the Inflammasome in Intestinal Epithelial Cells

Findings indicate that genetically very similar E. coli strains differ markedly in their ability to activate the inflammasome, as compared to the commensal strain K12.

Escherichia coli Strain Nissle 1917 Ameliorates Experimental Colitis via Toll-Like Receptor 2- and Toll-Like Receptor 4-Dependent Pathways

Evidence is provided that E. coli Nissle 1917 ameliorates experimental induced colitis in mice via TLR-2- andTLR-4-dependent pathways.

Impact of a probiotic Enterococcus faecalis in a gnotobiotic mouse model of experimental colitis.

The potential of probiotic bacteria to initiate pro-inflammatory responses in the disease-susceptible but not the normal host is shown.

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

  • M. Schultz
  • Medicine, Biology
    Inflammatory bowel diseases
  • 2008
The unique combination of fitness and survival factors to support intestinal survival, the lack of virulence, and obvious probiotic properties make this microorganism a safe and effective candidate in the treatment of chronic inflammatory bowel diseases.

Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease.

Inflammatory bowel diseases (IBD) are chronic inflammatory conditions, characterised by remissions and relapses episodes, whose main manifestations are ulcerative colitis and Crohn's disease.

Polyphosphate, an active molecule derived from probiotic Lactobacillus brevis, improves the fibrosis in murine colitis.

  • S. KashimaM. Fujiya Y. Kohgo
  • Medicine, Biology
    Translational research : the journal of laboratory and clinical medicine
  • 2015

E. coli Nissle 1917 in the Treatment of Inflammatory Bowel Disease

There is convincing evidence that EcN is safe to use and equally effective as mesalamine in the maintenance of remission of ulcerative colitis and limited evidence that it may be effective in the treatment of irritable bowel syndrome, Crohn’s Disease and pouchitis.
...

References

SHOWING 1-10 OF 40 REFERENCES

Lactobacillus plantarum 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice

Results demonstrate that L. plantarum can attenuate immune-mediated colitis and suggest a potential therapeutic role for this agent in clinical inflammatory bowel diseases.

Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis.

In all models of experimental and spontaneous colitis examined, ISS-ODN administration ameliorated clinical, biochemical, and histologic scores of colonic inflammation and suggest a physiologic, anti-inflammatory role for immunostimulatory DNA in the GI tract.

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

The protective effects of Probiotics are mediated by their own DNA rather than by their metabolites or ability to colonize the colon, and live microorganisms are not required to attenuate experimental colitis because nonviable probiotics are equally effective.

Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment

It is suggested that antibiotics and probiotic agents provide synergistic therapeutic effects, perhaps mediated by altered immunomodulation with selective activity of different lactobacillus species in the prevention of recurrent colitis.

Effect of probiotic strains on interleukin 8 production by HT29/19A cells

The results suggest that probiotic Gram-positive bacteria and E. coli Nissle 1917 may exert their beneficial effects on the host by a different mechanism of action.

Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

Probiotic bacteria enhance murine and human intestinal epithelial barrier function.

In vitro studies showed that epithelial barrier function and resistance to Salmonella invasion could be enhanced by exposure to a proteinaceous soluble factor secreted by the bacteria found in the VSL#3 compound.

Functional modulation of enterocytes by gram-positive and gram-negative microorganisms.

  • J. OtteD. Podolsky
  • Biology
    American journal of physiology. Gastrointestinal and liver physiology
  • 2004
Probiotics and protein(s) released by these organisms may functionally modulate the intestinal epithelium of the host by different mechanisms, including the competition of whole organisms for contact with the epithelial surface as well as stabilization of the cytoskeleton and barrier function and the induction of mucin expression.